Skip to main content
. 2015 Jun 8;6(27):23987–24001. doi: 10.18632/oncotarget.4364

Figure 5. Mutant bvPTX3 (mbvPTX3) attenuates bvPTX3-induced stemness, drug resistance and migration/invasion of breast cancer cells.

Figure 5

A. A schematic representation of various recombinant forms of PTX3 (bvPTX3 or mbvPTX3). B. bvPTX3 and mbvPTX3 had no effect on the proliferation of MB231 cells. MB231 cells were exposed to the recombinant proteins mbvPTX3and mbvPTX3 and the proliferation of experimental cells was assessed at the 24th and 48th h. C. mbvPTX3 inhibited mbvPTX3-induced sphere formation by MB231 cells. MB231 cells were treated with mbvPTX3 or the Asn220-mutated mbvPTX3 [N-glycosylation site]. The number of spheres was calculated after 14 days. D. mbvPTX3 attenuated the mbvPTX3-induced drug resistance of MB231 cells. The viability of CDDP- or 5-FU-treated MB231 cells was calculated by incubating cells with mbvPTX3 or mbvPTX3 as indicated and further cell viability assays were conducted after 48 h. E. mbvPTX3 inhibited the mbvPTX3-induced in vitro migration and invasion of cancer cells. mcCDRMB231 (MBR) cells were seeded in the upper layer of a Boyden chamber. After 3 h, the culture medium was replaced with serum-free medium in the upper layer and bvPTX3 or mbvPTX3, as indicated, were added to serum-free medium in the bottom layer.